Adolescent Idiopathic Scoliosis (AIS) Clinical Trial
— MID-COfficial title:
Safety and Effectiveness Evaluation of the Minimal Invasive Deformity Correction (MID-C) System in Adolescent Idiopathic Scoliosis (AIS)
Verified date | February 2017 |
Source | Apifix |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
Adolescent idiopathic scoliosis (AIS) is a common disorder of unknown etiology in which the
vertebrae and discs gradually develop a curvature that is first detected in patients between
11 and 20 years of age. The deformity is 3-dimensional, with a coronal curve measured from
radiographs by the Cobb angle .
The Cobb angle measurement of scoliosis represents the sum of the angular wedging of each
vertebra and disc between the superior and inferior end vertebrae . Although a small curve
is well tolerated and does not require treatment, a large curve can progress to the point
that it is cosmetically unacceptable, interferes with chest wall mechanics, and produces
cardiac and pulmonary compromises. The natural history of AIS apparently includes 2 stages:
the initiation of the curve and its subsequent progression. The factors responsible for the
initiation of the curve are unknown, but the subsequent progression of the curve is clearly
associated with the adolescent growth spurt . The primary risk factors for progression
include age at onset and the magnitude of the curve; young patients with large curves are at
the highest risk .
Although numerous treatment methods have been recommended for patients with AIS, the only
accepted treatment includes bracing for skeletally immature patients with curves between 25
and 40 degrees and operative correction with spinal fusion for patients with curves greater
than 45 degrees. For many teenagers, the cosmetic and social concerns associated with
bracing has caused compliance problems with wearing the brace and many patients only wear
the brace at home . While operative intervention completely corrects the scoliosis or rib
hump, it eliminates segmental spinal motion, and concentrates stresses at the ends of the
fusion potentially leading to disc degeneration and back pain.
Despite satisfactory short-term results of operative instrumentation and fusion, a less
invasive technique preserving more motion with a smaller scar represents a major
improvement. Realizing this goal is contingent on treating curves early, before they
progress to an irreversible deformity, and when there is still enough residual growth and
remodeling potential.
ApiFix Ltd has developed a novel implant for less invasive treatment of AIS. The MID-C
system is designed to correct the deformity step by step along a period of time, giving the
skeletal and soft tissues time to accommodate any incremental correction.
The MID-C System inherent benefits are:
- Only two screws are used
- Incision size is much smaller
- Simpler operation with shorter operative time
- Less complications (attributed to the three points above).
- Minimal spinal mobility loss.
All the device components are made of materials well accepted in the orthopedic field and
are fully biocompatible (see Investigator Brochure).
The unique concept of the system and the materials used may provide favorable results as
follows: Smaller scare, quicker healing period and better spine mobility over the years.
This study is designed to demonstrate that the MID-C System is safe and effective.
Status | Completed |
Enrollment | 13 |
Est. completion date | April 2016 |
Est. primary completion date | April 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 11 Years to 20 Years |
Eligibility |
Inclusion Criteria: 1. Adolescence above and inclusive 11 years old 2. Minimum of 35 degrees Cobb angle, confirmed by X-ray. Lenke type 1 or 5 3. Completed at least 6 months of conservative therapy (e.g., P.T., bracing, traction, or others). 4. Reisser sign of 2 to 4 5. Appropriate candidate for posterior surgical approach 6. Subject has Good general health. 7. Subject has no hypersensitivity and allergies to Titanium 8. Subject guardians willing to sign a written informed consent form (ICF).surgeon Exclusion Criteria: 1. Cobb angle over 55 degrees 2. Other non idiopathic scoliosis. 3. AIS which is not defined as Lenke type 1 or 5 4. Previous spine surgery. 5. Allergy to any component of the device. 6. Active systemic disease, such as AIDS, HIV, or active infection 7. Back or leg pain of unknown etiology 8. Systemic disease that would affect the subject's welfare or overall outcome of the study. 9. Mentally compromised |
Country | Name | City | State |
---|---|---|---|
Hungary | University of Pecs | Pecs | |
Romania | Maria Sklodowska Curie | Bucharest | |
Romania | Spitalul de Copii Sf. Maria | Iasi |
Lead Sponsor | Collaborator |
---|---|
Apifix |
Hungary, Romania,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | No Device related Serious Adverse Event | 2 years | ||
Primary | No significant curve progression above or below the implant | 6 months, 1 year, 2 years | ||
Secondary | Minimum of 50% deformity correction within 6 months | 6 months | ||
Secondary | Evaluate the correction period using X-ray | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02285621 -
Validation of a New Generation of Optimized Orthoses for Personalized Treatment of Adolescent Idiopathic Scoliosis
|
N/A | |
Recruiting |
NCT05774002 -
Psychological Assessment of Scoliosis Patients Undergoing Surgical Management
|
N/A | |
Terminated |
NCT02200302 -
Safety and Effectiveness Evaluation of the Minimal Invasive Deformity Correction (MID-C) System in Adolescent Idiopathic Scoliosis (AIS)
|
N/A | |
Not yet recruiting |
NCT06365892 -
Open-label Placebo (COLP) for Pain in Adolescent Idiopathic Scoliosis (AIS) Surgery+Surgical Treatment of Idiopathic Scoliosis
|
Phase 2/Phase 3 | |
Completed |
NCT03071471 -
Feasibility Evaluation Study of the MID-C Device
|
N/A | |
Recruiting |
NCT05561725 -
Perioperative Steroid Dosing on the APR in AIS
|
Phase 4 |